
AMD Earnings Fail to Impress, Novo Nordisk Cuts Outlook Amid Obesity Drug Pricing Pressure
The Rundown
00:00
Novo Nordisk Lowers Outlook Amid Pricing Pressure
Zaid details Novo Nordisk's lowered guidance, GLP-1 pricing talks with the U.S., WeGovie sales, and Metsera bidding war.
Play episode from 03:38
Transcript


